Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 18/20 | 0.60 |
| ▸ | SGK1 | O00141 | 1/20 | 0.60 |
| ▸ | KIT | P10721 | 5/20 | 0.52 |
| ▸ | HSPB1 | P04792 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.52 |
| ▸ | LCK | P06239 | 4/20 | 0.52 |
| ▸ | KDR | P35968 | 4/20 | 0.52 |
| ▸ | CSF1R | P07333 | 1/20 | 0.52 |
| ▸ | MAPK9 | P45984 | 3/20 | 0.51 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.51 |
| ▸ | MAPK13 | O15264 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2416719 | 0.96 | MAPK14 (0.65) | MAPK14SGK1KITHSPB1CYP2C9 | |
| SCHEMBL2416184 | 0.92 | MAPK14 (0.58) | MAPK14SGK1KITHSPB1CYP2C9 | |
| SCHEMBL2416565 | 0.91 | MAPK14 (0.56) | MAPK14SGK1KITHSPB1CYP2C9 | |
| SCHEMBL2418265 | 0.87 | MAPK14 (0.54) | MAPK14SGK1KITHSPB1CYP2C9 | |
| SCHEMBL9974686 | 0.86 | MAPK14 (0.52) | MAPK14SGK1KITHSPB1CYP2C9 | |
| SCHEMBL2422941 | 0.85 | MAPK14 (0.56) | MAPK14SGK1KITHSPB1CYP2C9 | |
| SCHEMBL2422133 | 0.85 | MAPK14 (0.54) | MAPK14SGK1KITHSPB1CYP2C9 | |
| SCHEMBL2418489 | 0.84 | MAPK14 (0.54) | MAPK14SGK1KITCYP2C9LCK | |
| SCHEMBL2418495 | 0.84 | MAPK14 (0.52) | MAPK14SGK1KITHSPB1CYP2C9 | |
| SCHEMBL2418175 | 0.84 | MAPK14 (0.52) | MAPK14SGK1KITHSPB1CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2144881-B1 | ISOQUINOLINONE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE IN THE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE ( COPD ) AND ASTHMA | ASTRAZENECA AB (SE) | 2012-06-20 | — | — | EP | disclosed |
| EP-2144881-B1 | ISOQUINOLINONE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE IN THE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE ( COPD ) AND ASTHMA | ASTRAZENECA AB (SE) | 2012-06-20 | — | — | EP | disclosed |
| US-8012979-B2 | Compounds and their uses 707 | ASTRAZENECA AB (SE) | 2011-09-06 | — | — | US | disclosed |
| US-8012979-B2 | Compounds and their uses 707 | ASTRAZENECA AB (SE) | 2011-09-06 | — | — | US | disclosed |
| US-8012979-B2 | Compounds and their uses 707 | ASTRAZENECA AB (SE) | 2011-09-06 | — | — | US | disclosed |
| US-20090023746-A1 | COMPOUNDS AND THEIR USES 707 | ASTRAZENECA AB (SE) | 2009-01-22 | — | — | US | disclosed |
| US-20090023746-A1 | COMPOUNDS AND THEIR USES 707 | ASTRAZENECA AB (SE) | 2009-01-22 | — | — | US | disclosed |
| US-20090023746-A1 | COMPOUNDS AND THEIR USES 707 | ASTRAZENECA AB (SE) | 2009-01-22 | — | — | US | disclosed |
| WO-2008122765-A1 | NEW COMPOUNDS AND THEIR USES 707 | ASTRAZENECA AB (SE) | 2008-10-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023746-A1 | COMPOUNDS AND THEIR USES 707 | CYP3A7, UGT1A7, UGT2B7 | MAPK14 4537/4885SGK1 2470/4885KIT 387/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.